NCT02298959 2026-04-13Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced CancerNational Cancer Institute (NCI)Phase 1 Active not recruiting59 enrolled
NCT02465060 2026-04-13Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting6,452 enrolled 2 FDA